蒲 若 芳
輔仁大學 數據科學中心 執行長
台北醫學大學醫務管理學系所 兼任助理教授
地址：新北市新莊區中正路510號 輔仁大學 國璽樓
MD380
聯絡電話：02-
2905 6494
更新日期: 2024 -4 - 11
A.
學歷
1991 臺灣大學公共衛生學系畢業
1993 臺灣大學公共衛生研究所流行病學組碩士 (MS)
2002 臺灣大學流行病學研究所流行病學組博士 (PhD)
B.
經歷
|
2023.4~迄今 |
輔仁大學數據科學中心執行長 |
|
|
2017.9~迄今 |
輔仁大學兼任助理教授 |
|
|
2016.12~2023.1 |
衛生福利部國家C型肝炎旗艦計畫辦公室（2019年12月改名為衛生福利部國家消除C肝辦公室） 主任 |
|
|
2015.9~2016.8 |
臺灣大學健康資料研究中心 資深研究員 |
|
|
2010.7~2015.8 |
財團法人醫藥品查驗中心醫藥科技評估組組長 |
|
|
2009.12~2010.6 |
財團法人醫藥品查驗中心醫藥科技評估組代組長 |
|
|
2007.9~2009.11 |
財團法人醫藥品查驗中心醫藥科技評估組研究員 |
|
|
2006~迄今 |
台北醫學大學醫務管理學系所 兼 |
|
|
1999~2007 |
日祥醫事管理顧問股份有限公司 研究總監 |
|
|
|
|
|
|
C.
諮詢 |
|
|
|
2019 |
國家衛生研究院論壇108年研究主題 「預防接種服務財務解決對策」委員會委員 |
|
|
2019.1~ |
聯愛工程HTA中心學術顧問委員會委員 |
|
|
2019~2020 |
衛生福利部社保司「全民健保醫療給付費用總額基期費用檢討」工作小組 |
|
|
2014~2015,
2017~2021, 2024~ |
疾病管制署諮詢委員 |
|
|
2020.2~2023.2,
2024.2~2028.1 |
癌症希望基金會學術委員 |
|
|
|
|
|
|
|
|
|
D.
學會參與
|
2024~ |
(ISPOR) Value in Health Regional Issues Editorial Board member |
|
2021 2019~2020 |
HTAi Policy Forum Advisory Committee Member, International Scientific Program Committee, HTAi 2020 |
|
Member, Program Committee (Public Health), 2020 ISVHLD Global
Hepatitis Summit |
|
|
2018~2021 |
Board of Director, International Society International Society For Pharmacoeconomics
and Outcomes Research (ISPOR) |
|
2018~2019 |
Co-Chair, International Scientific Program Committee, HTAi 2019 |
|
2014~2016 |
International Organizing Committee,
Prince Mahidol Award Conference 2016 |
|
2015~2016 |
President, HTAsiaLink |
|
2011~2019 |
Board, HTAsiaLink |
|
2010~2012 |
INAHTA Board Director |
|
2006~2012 |
Supervisory board member, Taiwan
Society for Pharmacoeconomics and Outcomes (TASPOR) |
|
2003~2006 |
Board member, TASPOR |
E.
近期跨國研究參與
1.
HTA guideline Project (A stepwise
guide for HTA guideline development), initiated by HITAP
International Unit (HIU), National University of Singapore (NUS), and KEMRI
Wellcome Trust.
2.
RWE for HTA in
Asia (REALISE) Working Group, initiated by Saw
Swee Hock School of Public Health and HITAP.
(2019-2020)
3.
APAC Liver Disease Alliance.
4.
HTA for All.
F.
近期國內研究或倡議參與
1.
立法院厚生會「提升台灣癌症新藥可近性委員會」第二屆學術委員
2.
智慧病人領袖學院院長
3.
癌症希望基金會學術研究委員會 (2024-2028)
4.
「罕見疾病創新治療及藥物給付政策白皮書」計畫共同主持人
(2023)
5.
國家衛生研究院論壇「健保藥物給付多重決策模式」研究參與
(2023)
6.
「臺灣子宮頸癌篩檢政策建言書」撰寫參與
G.
期刊同儕審閱參與
u
Journal of
Hepatology
u
Value in
health
u
Value in
health regional issue
u
Cephalalgia
u
International
Journal of Technology Assessment in Health Care
u
BJOG
u
JFMA
u
JGH
u
Journal of
Oncology
u
Vaccine
u
PLOS ONE
u
Frontiers
u
Public Health
in Practice
u
Health Systems
and Reform
u
Asia Pacific
Journal of Public Health
u Dentist
u
The Lancet
Regional Health – Southeast Asia
H. 論文著作
l 楊雯雯、鄭燕淑、蒲若芳（2024）。罕見疾病藥物納保審查機制與改革方向。月旦醫事法報告，202406 (92期)，127-147。
l Pwu RF, Cheng YS, Yang WW, Wu GH. The Development of Health Technology Assessment in Taiwan: Perspectives and Analysis. Health Syst Reform. 2023 Dec 31;9(3):2330396. doi: 10.1080/23288604.2024.2330396. Epub 2024 May 7. PMID: 38715195.
l
楊雯雯、吳慧敏、劉嘉玲、鄭國本、余明隆、蒲若芳、盧勝男、簡榮南（2023）。C型肝炎病毒抗體快篩試劑的運用。台灣公共衛生雜誌，42(6)，594-611。
l
Yang WW, Juan YC, Wu GHM, Pwu RF. The Critical Intersect of
Regulations, Health Technology Assessment, and Drug Safety Assessments. Drug
Saf (2023). https://doi.org/10.1007/s40264-023-01386-1
l
Rong-Nan Chien, Sheng-Nan Lu, Grace Hui-Min Wu, Wen-Wen Yang, Raoh-Fang
Pwu, Chia-Ling Liu, Kuo-Pen Cheng, Shih-Chung Chen, Chien-Jen Chen, Policy and
Strategy for Hepatitis C Virus Elimination at the National Level: Experience in
Taiwan, The Journal of Infectious Diseases, Volume 228, Issue Supplement_3, 15
September 2023, Pages S180–S188, https://doi.org/10.1093/infdis/jiad016
l
Chen CC, Lai CH, Chang CL, Cheng WF, Pwu RF, Tsai J, Wang PH,
Whang-Peng J, Lai GM, Managing the transition in cervical screening methods for
Taiwan: Policy recommendations and perspectives, Journal of the Formosan
Medical Association, 2023, (in press) https://doi.org/10.1016/j.jfma.2023.06.018.
l
楊雯雯、劉嘉玲、吳慧敏、鄭國本、盧勝男、簡榮南、蒲若芳. 推動消除C肝政策之回顧. 台灣衛誌；2023:42(2):165-179.
l
KC, S., Lin, L. W., Bayani, D. B. S., Zemlyanska, Y., Adler,
A., Ahn, J., Chan, K., Choiphel, D., Genuino-Marfori, A. J., Kearney, B., Liu,
Y., Nakamura, R., Pearce, F., Prinja, S., Pwu, R., Shafie, A. A., Sui,
B., Suwantika, A., Tunis, S., Wu, H., Zalcberg, J., Zhao, K., Isaranuwatchai,
W., Teerawattananon, Y., & Wee, H. (2023). What, Where, and How to Collect
Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement
Decision-Making in Asia: A reflection into the Past and A Way Forward. International
Journal of Health Policy and Management, 12(1), 1-9. doi:
10.34172/ijhpm.2023.6858
l
Shiroiwa,
T., Murata, T., Ahn, J., Li, X., Nakamura, R., Teerawattananon, Y., Kun, Z.,
Shafie, A. A., Valverde, H., Lam, H., Ng, K., Nadjib, M., Pwu, R. F.,
Nugraha, R. R., Chen, Y. C., & Fukuda, T. (2022). Developing a New
Region-Specific Preference-Based Measure in East and Southeast Asia. Value
in health regional issues, 32, 62–69. https://doi.org/10.1016/j.vhri.2022.07.002
l
楊雯雯、吳慧敏、盧勝男、劉嘉玲、鄭國本、蒲若芳. 滾動調整2025年C肝消除治療目標數. 台灣衛誌；2022:41(6):567-71.
l Husereau D, Drummond M,
Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L,
Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu
RF, Staniszewska S.
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022)
Statement: Updated Reporting Guidance for Health Economic Evaluations. Value
Health. 2022; 25: 3-9.
l Husereau D, Drummond M,
Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L,
Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu
RF, Staniszewska S.
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022
Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices
Task Force. Value Health. 2022; 25: 10-31.
l Lu
CY, Tang CH, Fu T, Pwu RF, Ho YF. Pneumococcal conjugate vaccines in
Taiwan: Optimizing health gains in children and older adults through
constrained optimization modeling: Pneumococcal conjugate vaccines optimization
in Taiwan. Int J Infect Dis. 2021. Nov 5;S1201-9712(21)00851-1. doi: 10.1016/j.ijid.2021.10.058.
l Chien RN, Lu SN, Pwu RF, Wu GH, Yang WW, Liu CL. Taiwan accelerates
its efforts to eliminate hepatitis C. Glob Health Med. Released July 05, 2021.
Online ISSN 2434-9194. Doi:https://doi.org/10.35772/ghm.2021.01064.
l Wu GHM, Yang WW, Liu CL, Pwu RF, Chien RN, Lee PC, Chen SC, Chen DS,
Lu SN. The epidemiological profile of chronic hepatitis C with advanced hepatic
fibrosis regarding virus genotype in Taiwan: A nationwide study. J Formos Med
Assoc, 2021; 120: 1444-51.
l Lou J, KC S, Toh K, Dabak S, Adler A, Ahn J, Bayani D, Chan K, Choiphel D,
Chua B, Genuino AJ, Guerrero AM, Kearney B, Lin LW, Liu Y, Nakamura R, Pearce
F, Prinja S, Pwu RF, Shafie AA, Sui B, Suwantika A, Teerawattananon Y,
Tunis S, Wu HM, Zalberg J, Zhao K, Isaranuwatchai W, Wee HL. Real-world data
for health technology assessment for reimbursement decisions in Asia: Current
landscape and a way forward. International Journal of Technology Assessment in
Health Care. 2020, 1-7. doi:10.1017/S0266462320000628
l Shiv K Sarin, Manoj Kumar, Mohammed Eslam, Jacob George, Mamun Al Mahtab,
Sheikh M Fazle Akbar, Jidong Jia, Qiuju Tian, Rakesh Aggarwal, David H Muljono,
Masao Omata, Yoshihiko Ooka, Kwang-Hyub Han, Hye W Lee, Wasim Jafri, Amna S
Butt, Chern H Chong, Seng G Lim, Raoh-Fang Pwu, Ding-Shinn Chen. Liver
diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology
Commission. The Lancet Gastroenterology & Hepatology. 2020;5(2):167-228. https://doi.org/10.1016/S2468-1253(19)30342-5
l
劉嘉玲、楊雯雯、吳慧敏、鄭國本、蒲若芳. 臺灣 C 型肝炎消除的國家政策與軌跡. 愛之關懷. 2019;109:6-16.
l Teerawattananon Y, Rattanavipapong W, Lin L, Dabak S, Gibbons B,
Isaranuwatchai W, Toh K, Cher B, Pierce F, Bayani D, Nakamura R, Pwu
R, Shafie A, Adhikari D, Prinja S, Babidge, W. Landscape analysis of
health technology assessment (HTA): Systems and practices in
Asia. International Journal of Technology Assessment in Health Care,
2019;35(6):416-421. doi:10.1017/S0266462319000667
l
從英國發展早期感知與預警系統的經驗為例，看台灣健康照護體系之應用. 楊雯雯、蒲若芳. 台灣衛誌 2019；38(3)：236-251.
l Teerawattananon Y, Luz K, Yothasmutra C, Pwu RF, Ahn J, Shafie AA,
Chalkidou K, Tantivess S, Santatiwongchai B, Rattanavipapong W, Dabak S. HISTORICAL
DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF
SUCCESS. International Journal of Technology Assessment in Health
Care, 2018;34(3), 260-266. doi:10.1017/S0266462318000223
l Shantakumar S, Pwu RF, D’Silva L, Wurst K, Kuo YW, Yang YY, Juan
YC, Chan KA. Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide
population-based study. BMC Pulm Med. 2018;18(1):16
l Wu GH, Pwu RF, Chen SC. Achieving hepatitis C elimination
in Taiwan-Overcoming barriers by setting feasible strategies. J Formos Med
Assoc, 117 (2018), pp. 1044-1045
l Hailey D, Werko S, Rosen M, Macpherson K, Myles S, Gallegos Rivero V,
Hipolito-Olivares C, Sihvo S, Pwu RF, Yang WW, Chen YC, Perez Galan A,
Aleman A, Villamil E. Influence of Health Technology Assessment and Its
Measurement. Int J Technol Assess Health Care 2016;32(6): 376-384.
l Chiu WT, Pwu RF, Gau CS. Affordable health technology assessment in
Taiwan: A model for middle-income countries. J Formos Med Assoc.
2015;114(6):481-3.
l Soon SS, Lopes G, Lim HY, Wong-Rieger D, Bahri S, Hickinbotham L, Jha A,
Ko BS, MacDonell D, Pwu RF, Shih R, Sirachainan E, Suh DC, Wale J, Zhang X, Wee
HL. A call for action to improve access to care and treatment for patients with
rare diseases in the Asia-Pacific region. Orphanet J Rare Dis. 2014; 9: 137.
l Tan EC, Pwu RF, Chen DR, Yang MC. Is a diabetes pay-for-performance
program cost-effective under the National Health Insurance in Taiwan? Qual Life
Res. 2014;23(2):687-96.
l Hailey D, Werko S, Bakri R, Cameron A, Gohlen B, Myles S, Pwu RF, Yothasamut J. Involvement of consumers in
health technology assessment activities by Inahta agencies. Int J Technol
Assess Health Care. 2013;29(1): 79-83.
l Aljunid SM, Srithamrongsawat S, Chen W, Bae SJ, Pwu RF, Ikeda S, et
al. Health-Care Data Collecting, Sharing, and Using in Thailand, China
Mainland, South Korea, Taiwan, Japan, and Malaysia. Value in health.
2012;15(1):S132-S8.
l Chow IH, Tang CH, You SL, Liao CH, Chu TY, Chen CJ, Chen CA, Pwu RF.
Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear
for cervical cancer screening in a publicly financed health-care system. Br J
Cancer 2010;103:1773-82.
l Pwu RF, Liu CY, Ko SY, Tsai IC,
Yang YK. Pharmacoeconomic evaluation of paliperidone extended release versus
olanzapine or quetiapine in the treatment for patients with schizophrenia in
Taiwan. Taiwanese Journal of Psychiatry [Taipei] 2010; 24: 281-91.
l Liao CH, Liu JT, Pwu RF, You SL, Chow I, Tang CH. Valuation of the
economic benefits of human papilomavirus vaccine in Taiwan. Value in Health,
2009, 12(S3), S74-77.
l Tang CH, Pwu RF, Tsai IC, Wang HI, You SL, Chen CA, Scuffham PA,
Hsieh CY, Chou CY, Lin SR, Chen YD, Chen CJ. Costs of cervical cancer and
precancerous lesions treatment in a publicly financed health care system. Arch
Gynecol Obstet 2009.
l Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha, EH. The
cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Asian Pacific J Cancer Prev 2008; 9 (3): 459-566.
l Lacey L, Chien RN, Chuang WL, Pwu RF. Economic evaluation of
chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol. Apr
2008;23(4):571-579.
l Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Risk estimates for drugs
suspected of being associated with Stevens-Johnson syndrome and toxic epidermal
necrolysis: a case-control study. Internal Medicine Journal 2005;
35 (3):188-190.
l Wang SJ, Fuh JL, Juang KD, Lu SR, Hsu LC, Chen WT, Pwu RF.
Evolution of migraine diagnosis in adolescents: a 3-year annual survey.
Cephalalgia 2005; 25(5):333-8.
l Hsu HC, Pwu RF. Too Late to Quit? Effect of Smoking and Smoking
Cessation on Morbidity and Mortality Among the Elderly in a Longitudinal Study.
The Kaohsiung Journal of Medical Sciences 2004; 20(10):484-91.
l Fuh JL, Pwu RF, Wang SJ, Chen YH. Measuring Alzheimer’s Disease
Progression with Transition Probabilities in the Taiwanese Population.
International journal of geriatric psychiatry 2004; 19(3):266-70.
l Pwu RF, Chan KA.
Cost-effectiveness analysis of interferon-alpha therapy in the treatment of
chronic hepatitis B in Taiwan. J Formos Med Assoc 2002;101:632-41.
l Chen CJ, You SL, Pwu RF, Wang LY, Lin YP, Hsi GC, Hsi MS, Ho
HC, Lee CT, Lin CG and et al. Community-based cervical cancer screening in
seven townships in Taiwan. Journal of the Formosan Medical Association 1995;94
:S103-11
I.
專書篇章
1.
蒲若芳、楊雯雯、吳慧敏。追求分配正義建立臺灣NICE。載於黃煌雄、江東亮（主編）， 第三波健保改革之路（頁137-164）。台北市：遠見天下文化
2.
湯澡薰、吳慧敏、蒲若芳。健康經濟與經濟評估。載於吳肖琪、鄭守夏(編輯)，衛生行政與管理。台北市：財團法人陳拱北醫學基金會
J.
Research Reports
1.
Besley, S., Cole, A., Pwu, R., Hsieh, C. (2023) Real-World
Evidence: Current Best Practice for Reimbursement Decision-Making. OHE Contract
Research. Available from
https://www.ohe.org/publications/real-world-evidence-current-best-practicebursement
Decision-Making. OHE Contract Research. Available from https://www.ohe.org/publications/real-world-evidence-current-best-practice
2.
罕見疾病創新治療及藥物給付建言書. (2023) 蔡輔仁、曾敏傑、蒲若芳、楊銘欽、陳莉茵、簡穎秀、蔡甫昌。財團法人罕見疾病基金會。
